Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
eFFECTOR Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
EFTR
Nasdaq
8731
https://effector.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for eFFECTOR Therapeutics Inc
eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
- Apr 9th, 2024 12:00 pm
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
- Apr 4th, 2024 12:30 pm
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Mar 25th, 2024 8:01 pm
eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Feb 5th, 2024 1:30 pm
eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- Jan 29th, 2024 9:05 pm
eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- Jan 25th, 2024 1:00 pm
eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024
- Jan 9th, 2024 1:05 pm
eFFECTOR Therapeutics Announces Reverse Stock Split
- Jan 9th, 2024 1:00 pm
eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients
- Dec 8th, 2023 1:15 pm
eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer
- Nov 28th, 2023 1:00 pm
eFFECTOR to Present New Clinical Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Patients with ER+ Metastatic Breast Cancer at SABCS 2023 Annual Meeting
- Nov 15th, 2023 1:00 pm
eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Nov 13th, 2023 9:14 pm
eFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare Conference
- Nov 6th, 2023 1:00 pm
eFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Acute Myeloid Leukemia
- Oct 24th, 2023 12:00 pm
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences
- Aug 30th, 2023 12:00 pm
eFFECTOR Therapeutics First Half 2023 Earnings: US$0.41 loss per share (vs US$0.093 loss in 1H 2022)
- Aug 11th, 2023 10:05 am
eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Aug 8th, 2023 8:01 pm
eFFECTOR Therapeutics Raises a Total of $16.2 Million in Gross Proceeds from Two Recent Registered Direct Offerings
- Jun 8th, 2023 8:01 pm
eFFECTOR Therapeutics Announces $8.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- Jun 7th, 2023 12:00 pm
eFFECTOR Therapeutics Announces Closing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- May 31st, 2023 9:43 pm
Scroll